The Case of Flecainide Toxicity: What to Look for and How to Treat.
Document Type
Article
Publication Date
8-1-2020
Publication Title
The Journal of Emergency Medicine
Abstract
BACKGROUND: Flecainide is a class Ic antidysrhythmic agent used to prevent and treat both ventricular and supraventricular tachycardias, including atrial fibrillation, atrioventricular nodal re-entrant tachycardia, and Wolff-Parkinson-White syndrome. Flecainide can cause serious side effects, including cardiac arrest, dysrhythmias, and heart failure. Despite its growing use, the presenting signs and symptoms of flecainide toxicity are not familiar to most clinicians. In particular, our patient's particular presentation of acute kidney injury (AKI) resulting in flecainide accumulation is high risk for missed diagnosis in the emergency department.
CASE REPORT: A 58-year-old woman presented with altered mental status and hypoxia that was later found to be secondary to sepsis. Medical history was notable for atrial fibrillation, for which she was on flecainide. Laboratory results were notable for hypokalemia and an AKI. Her wide complex tachycardia on admission was ultimately attributed to flecainide toxicity in the setting of AKI. Six days after presentation, it was found that her flecainide level was in the toxic range at 2.02 μg/mL (normal range 0.20-1.00 μg/mL, toxic >1.50 μg/mL). WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Flecainide intoxication is rare but serious due to the potential for cardiogenic shock. Its diagnosis can be difficult, as the flecainide serum level may take days to result. This case demonstrates the necessity of keeping flecainide toxicity on the physician's differential for patients who are taking the drug, as well as what electrocardiogram findings suggest it as the etiology. Treatment can be lifesaving if initiated promptly.
Volume
59
Issue
2
First Page
43
Last Page
43
Recommended Citation
Newson JM, Santos CD, Walters BL, Todd BR. The Case of Flecainide Toxicity: What to Look for and How to Treat. J Emerg Med. 2020 Aug;59(2):e43-e47. doi: 10.1016/j.jemermed.2020.04.052. Epub 2020 Jun 11. PMID: 32536493.
DOI
10.1016/j.jemermed.2020.04.052
ISSN
0736-4679
PubMed ID
32536493